This study is designed as a phase III, prospective, randomized, open-label, multicenter clinical trial comparing GV1001 concurrent with Gemcitabine/Capecitabine versus Gemcitabine/Capecitabine alone in treating locally advanced and metastatic pancreatic cancer patients. Patients will be treated until disease progression and will be subject to follow-up until death.
Patients will be randomized equally between the two arms:
1. Gemcitabine and Capecitabine
2. GV1001+ Gemcitabine and Capecitabine
